Venous Thromboembolism and Testosterone Therapy in Klinefelter Syndrome.

The incidence of venous thromboembolic events in Klinefelter syndrome patients was approximately four-fold higher than in the general adult male population.

• The incidence of a venous thromboembolic event was 17.0 (95% confidence interval: 8.5–30.3) events per 10,000 person-years.
• This finding is consistent with previous studies that showed an increase rate ratio of between 2.1 and 12.1, dependent on age.
• 11 of 179 patients (6.1%) had at least one venous thromboembolic event.
• The median age of the first venous thromboembolic event was 35 years (range: 19–73 years).

There was no statistically significant association between receiving testosterone replacement therapy and suffering a venous thromboembolic event in Klinefelter syndrome patients.

• p=0.1 for the association between testosterone replacement therapy use and venous thromboembolic event occurrence.
• 118 of 179 patients (66%) had received testosterone replacement therapies prior to the clinic review.
• Only 5 of the 11 patients who experienced a venous thromboembolic event had received testosterone replacement therapies prior to the event.
• The cohort consisted of 179 patients with a median age of 35 years (interquartile range: 29–42 years).

Klinefelter syndrome is the most common genetic cause of male infertility, affecting approximately 1 in 660 men.

• Klinefelter syndrome is characterized by the presence of one or more extra X chromosomes.
• Literature studies suggest an increased risk of venous thromboembolic events in Klinefelter syndrome.
• Testosterone replacement therapies are commonly used in Klinefelter syndrome to improve well-being, body composition, and sexual function.

The study cohort was drawn from a hospital-based Klinefelter syndrome clinical database with a relatively young median age.

• 179 patients were included in the analysis.
• The median age was 35 years (interquartile range: 29–42 years).
• Data on venous thromboembolic events, testosterone replacement therapy usage, and demographics were obtained from a hospital-based Klinefelter syndrome clinical database.